ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
54 hedge funds and large institutions have $62.2M invested in ESSA Pharma in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 15 closing their positions.
8% less funds holding
Funds holding: 59 → 54 (-5)
9.05% less ownership
Funds ownership: 85.73% → 76.68% (-9%)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
48% less capital invested
Capital invested by funds: $119M → $62.2M (-$56.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$13.3M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$2.34M |
| 3 |
O
OrbiMed
New York
|
+$1.69M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.36M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$9.17M |
| 2 |
Blackstone Inc
New York
|
-$6.31M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.75M |
| 4 |
Morgan Stanley
New York
|
-$4.12M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.03M |
EPIX Hedge Fund Activity: Q3 2022 in Review
54 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q3 2022, worth a combined $62.2M — down 48% from $119M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of EPIX and 10 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 13 added.
The largest buyer was BVF Inc, adding an estimated $13.3M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $9.17M sold.
- 54 institutional investors held ESSA Pharma (EPIX) as of Q3 2022, down from 59 in Q2 2022.
- Funds reported $62.2M of ESSA Pharma stock for Q3 2022, down 48% quarter-over-quarter.
- 10 funds opened new ESSA Pharma positions in Q3 2022 and 15 closed out, a net change of -5 holders.
- The largest ESSA Pharma buyer in Q3 2022 was BVF Inc, an estimated $13.3M added.
- The largest ESSA Pharma seller in Q3 2022 was Janus Henderson Group, an estimated $9.17M sold.
Based on aggregated 13F filings for Q3 2022.